Related Experiment Videos

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

K Podar1, Y T Tai, F E Davies

  • 1Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

Blood
|July 4, 2001
PubMed

Insights

Vascular Endothelial Growth Factor (VEGF) directly impacts multiple myeloma (MM) and plasma cell leukemia (PCL) cells, influencing their proliferation and migration. Targeting VEGF signaling offers a new therapeutic approach for these incurable blood cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Multiple myeloma (MM) is an incurable plasma cell malignancy with a median survival of 3-4 years.
  • Understanding the molecular mechanisms driving MM progression is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the direct effects of vascular endothelial growth factor (VEGF) on multiple myeloma (MM) and plasma cell leukemia (PCL) cells.
  • To elucidate the signaling pathways involved in VEGF-mediated tumor cell proliferation and migration in MM.

Main Methods:

  • Cell-based assays were used to examine the impact of VEGF on MM and PCL cells.
  • Specific signaling pathways, including protein kinase C (PKC) and the Raf-1-MEK-ERK pathway, were investigated.

Main Results:

  • VEGF was found to directly affect MM and PCL cells.
  • VEGF stimulates tumor cell proliferation through a PKC-independent Raf-1-MEK-ERK pathway.
  • VEGF promotes tumor cell migration via a PKC-dependent pathway.

Conclusions:

  • VEGF plays a significant role in the pathogenesis of MM and PCL.
  • Targeting VEGF signaling pathways presents a promising therapeutic strategy for MM and PCL patients.

Related Concept Videos